On World Hemophilia Day 2026, Spherix Global Insights announces the publication of data revealing early but evolving uptake across novel
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients, increasing competitive switching, and a
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake.
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line
Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier
New report using real-world data cites care hurdles, need for multiple meds In the U.S., having sickle cell disease (SCD) continues to
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton,
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused
